Kymera Investor Day Presentation Deck

Pbo 100 50 -50 -100 SAD 6 85-93% Degr* SAD 7 89-95% Degr* Broad and Deep Inhibition of Disease Relevant Cytokines Effect Against LPS (TLR4)- or R848 (TLR7/8)-Stimulated Cytokine Induction in Whole Blood IFNY IL13 80% -51% -42% 27% IL6 IL8 16% 19% *Mean IRAK4 degradation in PBMC at 24-48h 30% -58%¹ -46%² -72%¹ -67%² IL10 IL12 IL17 IL23 TNFa 29% KYMERA ©2021 KYMERA THERAPEUTICS, INC. -45%² 19% LPS -40%² 22% -54%² -68%¹ -62%¹ -81%¹ -83%¹ -35%² -43%² -45%² Placebo (n = 14) 24% SAD 63 (n = 6) -31% SAD 7³ (n = 6) Mean (+SE) Maximum % Change from Baseline at 24 - 48 Hours Pbo SAD 6 -42%² SAD 7 1 = p value < 0.01; 2= p value < 0.05 350 200 150 100 50 -50 -100 IFNY 40% -78% -97%² KYMERA R&D DAY - December 16th, 2021 HA IL1B IL6 -12% -4% IL8 185% -78%¹ -60%¹ -33% IL10 19% IL12 -7% IL17 4% -45% -80%¹ -60%¹ R848 TNFa -8% -61% -92%¹ -88%¹ -54% -89%¹ -93%¹ -79%¹ -88%² 3Ex vivo cytokine assay was performed at 48h nadir (maximal degradation) only in cohorts 6-7 PAGE 30

View entire presentation